Nel ASA

Regulatory Filings • Jan 20, 2010

DiaGenic signs agreement with Ferrer inCode

DiaGenic signs agreement with Ferrer inCode

DiaGenic signs agreement with Ferrer inCode for distribution of ADtect®

in Spain, Germany, Belgium, the Netherlands, Luxemburg, France, Italy,

and Portugal.

DiaGenic announces that it has signed an agreement for exclusive

distribution of ADtect® in major European countries with Ferrer inCode,

a biotech subsidiary of Grupo Ferrer Internacional. ADtect® uniquely

uses peripheral blood as the sample material to provide early

non-invasive diagnosis of Alzheimer's disease.

"Early detection enables subsequent early initiation of active

management strategies which may preserve the patients' level of function

for longer and increases the chances of delaying the progression of the

disease", said DiaGenic CEO Erik Christensen, M.D., Ph.D. "Current

evidence suggests that pharmacological treatments and caregiver

interventions can delay entry into nursing homes, thus reducing

healthcare costs. However, these cost savings are not being realized

because many patients with Alzheimer's disease are either not diagnosed

or diagnosed at a late stage of the disease. We envisage ADtect® with

its rapid and convenient sample collection playing a front line role."

"As front runners in the field of personalized medicine, we are

delighted to offer ADtect® to professionals and patients in our core

markets. The field of CNS is fast moving and we will continue to see

important developments within treatment and medical care of Alzheimer

patients. Therefore we strongly believe in an easy to use and

non-invasive test such as ADtect® which can provide early detection of

Alzheimer's disease and thereby improve quality of life", said Alfredo

Gracia M.D., Ph.D, Ferrer inCode's Chief Scientific Officer.

Following this latest distribution agreement, for the period from year

2010 up to and including year 2013 cumulative minimum volumes ADtect® in

17 European countries total approximately 85,000 tests.

Please find joint press release attached.

Contact person:

Erik Christensen, CEO

Telephone: + 47 95939918

E-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to

create value for patients, partners, and investors by developing new and

more patient friendly methods for early detection of diseases. DiaGenic

is currently a world leader in analyzing gene expression signatures

related to disease in easily available clinical samples such as

peripheral blood. This unique method is based on the principle that even

when a disease is localized at a specific part of the body, secondary

responses, which are also characteristic of the disease, can be measured

in other parts. Significant potential in numerous diseases such as

breast cancer and Alzheimer's disease has been identified. The company

has been granted patents in the U.S. and Europe. DiaGenic is listed on

the Oslo Stock Exchange. For more information visit www.diagenic.com

About Ferrer inCode and Grupo Ferrer Internacional

Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional,

working specifically in the field of personalized medicine as a provider

of diagnostic orientation, prognosis and prediction services based

chiefly on genomics, proteomics, metabolomics and bioinformatics. The

vision of Ferrer inCode is to help doctors make the most accurate

clinical decisions for every patient through advanced biotechnological

services. Grupo Ferrer Internacional is a privately held European

R&D-based pharmaco-chemical and medical device company headquartered in

Barcelona, Spain. Ferrer operates today in over 60 countries with the

overall aim of improving people's health and quality of life. Based on

its policy of continuous expansion throughout the world, Ferrer has

established strong industrial and commercial operations in Europe and

has extensive commercial experience in Latin America, Africa, the Middle

East and Far East. For more information on Ferrer,visit

www.ferrergrupo.com or www.ferrerincode.com.